Original language | English |
---|---|
Pages (from-to) | 465-478 |
Number of pages | 14 |
Journal | British Journal of Haematology |
Volume | 202 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1 Apr 2023 |
Bibliographical note
Funding Information:The BSH paid the expenses incurred during the writing of this guidance. All authors have made a full declaration of interests to the BSH and Task Force Chairs which may be viewed on request. WL has received speaker fees from Sanofi Aventis and Leo Pharma and speaker fees and attendance of advisory boards for Pfizer. CB has received speaker fees and financial support to attend scientific meetings from Sanofi Aventis and speaker fees and attendance of advisory boards for Pfizer.